BioTelemetry, Inc. (NASDAQ:BEAT) – Stock analysts at Dougherty & Co reduced their FY2018 earnings per share estimates for shares of BioTelemetry in a report issued on Monday. Dougherty & Co analyst G. Mannheimer now anticipates that the medical research company will post earnings per share of $1.40 for the year, down from their prior estimate of $1.42. Dougherty & Co currently has a “Buy” rating and a $40.00 price target on the stock.
Several other equities analysts have also recently issued reports on BEAT. BidaskClub cut BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Sidoti reissued a “buy” rating and issued a $49.00 price objective (up previously from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. Zacks Investment Research raised BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 price objective for the company in a report on Friday, August 11th. Off Wall Street started coverage on BioTelemetry in a report on Friday, September 15th. They issued a “sell” rating for the company. Finally, SunTrust Banks, Inc. started coverage on BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. BioTelemetry currently has an average rating of “Buy” and an average target price of $42.86.
COPYRIGHT VIOLATION WARNING: “Dougherty & Co Equities Analysts Lower Earnings Estimates for BioTelemetry, Inc. (BEAT)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/21/dougherty-co-equities-analysts-lower-earnings-estimates-for-biotelemetry-inc-beat.html.
Shares of BioTelemetry (NASDAQ BEAT) traded down $0.30 during mid-day trading on Tuesday, hitting $25.25. The stock had a trading volume of 402,800 shares, compared to its average volume of 476,313. The firm has a market cap of $828.03, a PE ratio of 35.00, a PEG ratio of 1.60 and a beta of 0.58. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75. BioTelemetry has a fifty-two week low of $18.60 and a fifty-two week high of $39.20.
BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.16 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by ($0.09). The company had revenue of $81.02 million during the quarter, compared to analyst estimates of $82.10 million. BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The business’s quarterly revenue was up 52.7% compared to the same quarter last year. During the same period last year, the firm earned $0.21 EPS.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BEAT. Winslow Evans & Crocker Inc. acquired a new position in BioTelemetry in the 3rd quarter worth about $109,000. Pinebridge Investments L.P. raised its holdings in BioTelemetry by 2.0% in the 2nd quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock worth $126,000 after purchasing an additional 75 shares during the period. Victory Capital Management Inc. raised its holdings in BioTelemetry by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the medical research company’s stock worth $140,000 after purchasing an additional 626 shares during the period. Dubuque Bank & Trust Co. acquired a new position in BioTelemetry in the 2nd quarter worth about $142,000. Finally, US Bancorp DE acquired a new position in BioTelemetry in the 2nd quarter worth about $145,000. 76.42% of the stock is owned by institutional investors.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.